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Abstract  The  procedure  of  maxillary  sinus  lifting  using  autogenous  bone  was  considered  the
reference  standard  choice  for  oral  rehabilitation  in  cases  of  severe  atrophic  maxilla.  However,  it
is not  always  a  viable  option,  due  to  the  limitations  or  morbidity  caused  by  grafting  techniques.
This has  led  to  the  development  of  bone  substitutes,  which  have  been  elaborated  and  improved.
Choosing  the  best  biomaterial  becomes  difﬁcult  due  to  the  wide  variety  of  bone  substitutes.
The aim  of  this  article  is  to  present  some  of  these  materials  that  are  reported  in  the  current
scientiﬁc literature  for  maxillary  sinus  lifting.
© 2016  Sociedad  de  Periodoncia  de  Chile,  Sociedad  de  Implantolog´ıa  Oral  de  Chile  y  Sociedad
de Pro´tesis  y  Rehabilitacio´n  Oral  de  Chile.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Seno  maxilar;
Consideraciones  actuales  sobre  sustitutos  óseos  en  elevación  del  seno  maxilarSustitutos  de  huesos;
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Resumen  El  procedimiento  de  elevación  del  seno  maxilar  utilizando  hueso  autógeno  se  con-
sideraba la  opción  estándar  de  oro  para  la  rehabilitación  oral  en  casos  de  maxilar  atróﬁco  grave.
Sin embargo,  no  siempre  es  una  opción  viable,  debido  a  las  limitaciones  o  a  la  morbilidad  cau-
sada por  técnicas  de  injerto,  lo  que  justiﬁca  la  existencia  de  sustitutos  óseos  que  han  sido
elaborados  y  mejorados.  En  cuanto  a  la  amplia  variedad  de  sustitutos  óseos,  se  hace  difícil
aterial.  El  objetivo  de  este  informe  es  presentar  una  variedad  dela mejor  elección  de  biom∗ Corresponding author.
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sustitutos  óseos  respetados  en  la  literatura  cientíﬁca  actual,  usados  en  la  elevación  del  seno
maxilar.
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Open Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Considering  the  limitations,  disadvantages  and  morbiditiesIntroduction
Over  the  past  40  years,  the  dental  implant  osseointegra-
tion  has  been  considered  the  greatest  scientiﬁc  discovery  for
dentistry,  since  its  ﬁrst  description  by  offering  an  alternative
of  oral  rehabilitation.1 However,  there  are  some  individual
limitations  including  the  bone  insufﬁciency,  which  is  com-
mon  after  tooth  loss  associated  with  absence  of  functional
stimulus  in  the  site.2 After  tooth  extraction,  the  alveolar
bone  undergoes  an  additional  atrophy  as  a  result  of  natural
remodeling  process.  This  process  begins  immediately  after
extraction  and  may  result  up  to  50%  of  ridge  width  resorp-
tion,  within  3  months.3 Deﬁciency  in  bone  volume  in  the
posterior  maxilla  is  one  of  the  most  common  problems  to
the  implantodontist  to  plan  an  implant  supported  prosthe-
sis.  This  is  because  the  maxillary  sinus  in  the  absence  of
teeth  tends  to  pneumatized  reducing  the  height  of  alveo-
lar  ridge,  hindering  the  installation  and/or  initial  stability
of  the  implant  required  to  the  prosthetic  support.  Against
this  problem,  authors  have  created  a  procedure  to  increase
bone  volume  of  atrophic  jaws  through  the  maxillary  sinus
lifting.3,4
In  the  literature,  the  autogenous  bone  graft  is  con-
sidered  as  ‘‘gold  standard’’,  because  it  presents  the
characteristics  considered  ideal:  osteogenesis,  osteoinduc-
tion  and  osteoconduction.5 However,  the  techniques  of
bone  grafting  and  partial  reconstruction  of  the  jaws  are
planned  according  to  the  degree  of  bone  loss,  surgi-
cal  prosthetic  planning,  the  patient’s  systemic  condition
and  the  viability  of  the  donor  area.  The  major  limita-
tion  of  intraoral  autogenous  bone  is  the  need  of  more
surgical  intervention  and  the  morbidity  of  the  donor
area,  apart  from  the  limited  amount  of  autogenous  bone.
Extraoral  donor  areas  also  have  some  disadvantages  or
limitations  such  as  the  need  for  hospitalization,  morbid-
ity  of  the  donor  area,  higher  cost  and,  particularly,  in
the  case  of  the  Iliac  crest,  one  post-operative  riskier  in
relation  to  infections,  injuries  to  nerves  and  functional
disability.6 In  addition,  there  are  reports  on  signiﬁcant  lev-
els  of  bone  reabsorption  when  only  the  autogenous  bone
is  used,  requiring  an  alternative  consideration  of  bone
substitutes.7,8
As  a  priority  to  minimize  patient’s  morbidity,  bone
substitutes  are  becoming  increasingly  improved.  On  the
wide  variety  of  bone  substitutes,  it  becomes  difﬁcult  to
choose  the  best  product.9,10 The  aim  of  this  paper  is  to
present  to  surgeon  dentist  the  variety  of  bone  substitutes
applied  in  maxillary  sinus  lifting,  enshrined  in  the  current
scientiﬁc  literature.
a
laterials and methods
he  proposal  of  this  study  was  to  inform  the  surgeon  on
uitable  bone  substitutes  regarding  the  world  scientiﬁc  lit-
rature.  The  search  was  based  on  scientiﬁc  researches
ublished  in  English  including  systematic  reviews  and  also
nimal  and  human  studies.  The  exclusion  criteria  were
ase  reports  and  discussion  articles.  The  inclusion  crite-
ia  assumed  the  studies  published  in  English  from  1980  to
014  searched  at  Medline  (Pubmed)  and  Bireme  databases.
he  keywords  ‘‘bone  substitute,’’  ‘‘bone  repair’’,  ‘‘bone
odeling’’,  ‘‘maxillary  sinus  lifting’’,  biomaterials’’  and
‘grafting’’  were  used  for  searching.
iterature review
undamental  considerations  on  bone  substitutes
here  are  four  main  characteristics  considered  ideal  in  bone
egeneration,  those  of  which  at  least  one  bone  substitute
ust  present.8,9 The  ﬁrst  main  feature  is  the  osteogene-
is  or  osteogenic  activity  (ability  of  bone  formation  from
iable  osteoblasts  or  pre-osteoblasts  derived  from  the  graft
onor  area,  which  are  capable  of  generating  cellular  prolif-
ration  and  producing  new  bone).8--11 The  second  property
s  the  osteoconduction  (the  capacity  of  the  graft  for  support
r  allow  cell  migration,  formation  of  blood  vessels  and  the
one  growth  in  surface),  and  the  osteoinductivity  (refers  to
he  ability  of  a  graft  to  induce  nondifferentiated  stem  cells
r  osteoprogenitor  cells  to  differentiate  into  osteoblasts).8,9
inally,  the  osseointegration,  which  is  the  ability  of  chemi-
al  contact  between  the  bone  surfaces  without  the  ﬁbrous
issue’s  presence.10 It  is  fundamental  the  presence  of  at
east  one  of  the  characteristics  described  above  and  only
utogenous  bone  presents  them  all.
Other  characteristics  considered  ideal  include:  the
emodeling  of  the  bone  initially  formed  in  mature  lamel-
ar  bone  as  a  function  of  time  passing,  ability  to  stabilize
mplants  when  installed  simultaneously  to  the  grafting
rocedure,  low  risk  of  infection,  good  availability,  low  anti-
enicity  and  physiologically  stable,  not  cause  rejection  and
e  ideally  be  absorbed  after  the  regeneration.11
lassiﬁcation  of  bone  substitutesssociated  with  use  of  autogenous  bone  in  maxillary  sinus
ifting,  bone  substitutes  were  introduced  as  an  alternative,
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sing  two  criteria  for  clinical  success:  osteoconduction
nd/or  osteoinduction.  The  major  advantages  are  easy
terilization,  storing,  handling  and  purchasing  the  bone  sub-
titute  based  on  the  preferences  and  needs  of  each  case.
hey  are  totally  synthetic  or  present  animal  origin.  The  bone
ubstitutes  of  animal  origin  may  be  derived  from  xenogenic
nd  allogenic  and,  those  fully  synthetic  or  alloplastic,  can  be
ivided  into:  polymers,  ceramics,  metallic  and  composites.
n  addition,  growth  factors  have  been  used  more  recently.9 In
his  work,  the  classiﬁcation  on  bone  substitutes  follows  some
uthors,9 which  takes  into  consideration  its  main  composi-
ion,  since  they  may  present  associations  of  more  than  one
aterial.
llogenic  bone  graft
he  allogenic  bone  implant  is  a  bone  substitute  widely  used
n  reconstructive  surgery  and  it  can  be  used  alone  or  in  com-
ination  with  other  biomaterials.  It  is  an  alternative  that
ffers  great  similarity  with  autologous  bone,  except  for  the
reservation  of  osteogenic  cells.  Furthermore,  it  has  osteo-
onductive  properties.11,12 Its  main  advantage  compared  to
utogenous  bone  is  the  elimination  of  a  second  surgical  site
o  reduce  morbidity  to  the  patient.9 Furthermore,  they  may
e  available  in  large  volumes  in  large  bone  defects,  also  they
re  capable  of  providing  structural  support.10 However  they
resent  some  limitations  such  as  the  absence  of  many  bone
ank,  high  cost  and  strict  control  to  prevent  disease  trans-
ission,  besides  presenting  negative  aspects  such  as  risk  of
nfection.  There  are  no  studies  presenting  long  follow  up.
The  allogenic  bone  grafts  are  demineralized  freeze-
ried  bone  allograft  (DFDBA)  and  demineralized  bone  matrix
DBM).  The  DBM  is  able  to  improve  bone  regeneration  by
heir  ability  osteoconductive.  They  can  often  be  associated
ith  alloplastic  biomaterials  or  xenogenic  grafts  to  supply
ome  deﬁciencies  property.13 Authors  demonstrated  that  the
mount  of  bone  formed  depends  on  how  the  DFDBA  is  used.13
Although  the  allogenic  bone  grafts  are  treated  by  various
ethods  considered  safe  such  as  freezing,  gamma  radiation
nd  ethylene  oxide,  the  risk  of  disease  transmission  from
onor  to  receptor  is  not  completely  removed.9 The  risk  of
acterial  infection  is  superior  with  increasing  size  of  the
raft  and  can  be  seen  in  more  than  10%  of  cases.  Viral  trans-
ission  is  a  potential  hazard,  especially  in  relation  to  hep-
titis  B,  C  and  HIV,  although  it  has  been  documented  unusual
oming  from  cadaver  donor.14 25  cases  of  infection  have
een  liked  to  this  type  of  implant.14 It  is  noteworthy  that,
lthough  many  methods  of  sterilization  are  able  to  reduce
he  risk  of  infection,  proteins  and  others  factors  responsible
or  osteoinductivity  tissue  are  eliminated.  It  is  noteworthy
hat  this  type  of  graft  is  banned  in  Europe  and  elsewhere.
Complications  associated  with  allogenic  bone  graft
nclude  fractures,  lack  of  osseointegration  and  infection.10
hen  allograft  is  performed  it  is  difﬁcult  to  evaluate  the
sseointegration.  Some  discrepancies  were  found  between
he  radiological,  clinical  and  microscopic  ﬁndings.  Absence
f  radiographic  aspects  of  osseointegration  can  be  expected
n  up  17%  of  cases  using  allogenic  bone  graft.9enogenic  bone  graft
one  substitutes  whose  main  component  is  derived  from
enogenic  bone  is  called  xenogenic  bone  graft.  Xenogenic
one  graft  most  commonly  used  is  from  bovine,  after  to
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reat  chemically  the  organic  components  and  to  leave
heir  mineral  structure.  Equine  and  porcine  sources  are
lso  common.  Another  source  is  from  the  exoskeleton  of
oral.  Xenogenic  bone  grafts  have  show  excellent  osteocon-
uctive  properties.12 Bio-Oss® (Geistlisch  Pharmaceutical,
olhusen,  Switzerland)  is  a bone  substitute  derived  from
eproteinized  bovine  bone  marrow,  with  the  hydroxyapatite
tructure  of  the  highly  porous  bone,  similar  to  the  cortical
one  of  the  human  species.  The  organic  components  are
emoved  chemically  or  heat  leaving  a  skeletal  support  for
steogenic  cells.  In  the  literature,  there  are  many  studies
hich  demonstrated  excellent  performance  as  a  bone  sub-
titute,  in  its  particulate  form  to  ﬁll  bone  defects.15,16 Also,
t  presents  osteoconductive  property  acting  as  a  scaffold  for
he  deposition  of  new  bone.  Studies  showed  a slow  degra-
ation  (between  3  and  4  years)  or  may  be  not  completely
egradable.16,17
Several  studies  on  animals  and  humans  have  demon-
trated  that  this  material  is  promising  in  comparison  with
ther  bone  substitutes,  because  in  maxillary  sinus  lifting
io-Oss® demonstrated  good  clinical  outcomes.17 Authors
escribed  an  efﬁcacy  about  80--100%  using  Bio-Oss®,  sug-
esting  as  effective  as  autogenous  bone.18 Authors  showed
vidence  of  an  increased  radiographic  density  and  stability
f  pure  mineralized  bovine  bone  as  a  graft  to  1.5  years  later,
n  the  absence  of  dental  implants.19
Evaluation  of  dental  implants,  installed  in  the  region  of
axillary  sinus  lifting  using  mineralized  bovine  bone  (MBB),
howed  63%  of  bone  formation  in  contact  with  the  implant
urface,20 27%,21 and  38%22 after  six  months  of  follow  up.
sing  only  the  MBB,  23%  of  newly  formed  bone  was  observed
t  12  weeks,  so  it  proved  to  be  slowly  reabsorbed  and  seems
o  behave  as  a semi-permanent  bone  substitute.16
Randomized  clinical  study  evaluated  10  patients,  two
ifferent  forms  of  treatment  in  each  maxillary  sinus:  a
esorbable  rigid  membrane  on  the  maxillary  sinus  and  in
he  other,  100%  of  Bio-Oss®.  The  results  after  6  months,
emonstrated  a  statistically  signiﬁcant  increase  of  bone
etween  the  groups  and  the  microscopy  of  the  bone  was
ormed  on  the  side  of  Bio-Oss® (36.1%)  group  compared
o  the  membrane  group  (24.2%).23 Authors  analyzed  these
atients  after  one  year  and  they  did  not  demonstrate  sta-
istically  signiﬁcant  difference  in  bone  loss  between  the
wo  groups  (mean  1.5  mm  in  the  membrane  group  and
.7  mm  in  the  in  Bio-Oss® group).12 In  addition,  differences
tatistically  signiﬁcant  were  not  presented  in  the  failure
f  implants,  neither  in  the  prostheses  between  the  two
roups.
eramic  compounds
he  bone  substitutes  made  of  ceramic  are  widely  used  asso-
iated  or  no  with  another  biomaterial.  There  are  many  types
f  calcium  phosphate  (CaP)  obtained  by  different  meth-
ds  of  synthesis  and  nowadays,  tricalcium  phosphate  (TCP)
nd  hydroxyapatite  (HA)  are  highly  sought.  Compounds
f  the  base  of  calcium  phosphate  (CaP)  have  excellent
iocompatibility,9,24 osteoconductive  activity,  and  they  are
iodegradable.25 HA  is  an  inorganic  compound  which  is  very
imilar  to  the  structure  of  the  mineral  phase  of  bone,  but
hows  weak  and  slow  degradation  (1--2%/year).12 However,
CP  presents  a  very  fast  biodegradation  rate,  and  is  not
lways  concurrently  with  the  bone  deposition.26
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fCurrent  considerations  on  bone  substitutes  
The  BoneCeramic® (Straumann®,  Basel,  Zwitzerland)  is
a  completely  synthetic  biomaterial  with  osteoconductive
property  which  favors  the  formation  of  vital  bone.27 It
is  composed  of  biphasic  CaP  (BCP),  a  combination  of  HA
(60  wt%  and  40%  TCP-B).  Studies  in  peri-implant  defects
demonstrated  bone  around  dental  implants  which  have  been
placed  in  alveoli  regeneration,  immediately  after  tooth
extraction.  Microscopic  and  radiographic  evaluation  demon-
strated  regenerated  bone  with  characteristics  similar  to
those  of  bone  located  in  areas  without  defect.27 However,
there  are  few  reports  using  such  material  in  humans  or  ani-
mals  so  that  the  authors  suggest  further  studies.27
Authors  classify  bioactive  glasses  and  ceramics  as  the
most  promising  fully  synthetic  ceramics,  because  they
are  inert,  biocompatible  and  they  present  osteoconductive
properties.28 Bone  substitutes  composed  of  bioactive  glass
are  reinforced  by  oxides  (sodium  oxide,  calcium  oxide,  phos-
phorus  pentoxide  and  silicon  dioxide)  and  they  allow  an
osseointegration  with  bone  tissue,  although  not  having  good
mechanical  strength.
Several  studies  have  examined  the  efﬁcacy  of  bone
substitutes  compounds  of  bioactive  glass  and  they  demon-
strated  osteoconductive  and  they  potentially  can  combine
ability  to  bond  to  tissues  (bioactivity).29 When  used  in
maxillary  sinus  lifting  of  25  patients,  Biogran® (Orthovita
e  3i,  ImplantInnovations,  Inc,  Palm  Beach  Gardens,  FL)
demonstrated  bone  growth,  proving  their  osteoconductive
properties.29 Studies  demonstrated  high  osteoconductive
property  followed  maxillary  sinus  lifting,  using  hydrate
bioactive  glass  with  saline  and  later  implant  placement,
suggesting  its  use  isolated  or  associated  with  autogenous
bone.30 Other  clinical  studies  have  also  indicated  this  bone
substitute  in  maxillary  sinus  lifting  procedure.31 The  main
advantages  offered  by  bioactive  glass  is  being  absorbable,
to  present  no  risk  of  disease  transmission  and  immune
responses  and  to  assist  in  hemostasis.  The  bioactive  ceram-
ics  exhibit  improved  mechanical  properties  relative  to
bioactive  glass,  but  they  are  still  brittle  enough  to  frac-
ture  when  subjected  to  cyclic  loading.  In  order  to  improve
its  resistance  to  fracture,  methods  of  incorporating  stain-
less  steel  and  zirconia  ﬁbers  have  been  performed.  The
use  of  Cerabone® (Botiss  dental  GmbH,  Berlin,  Germany)
is  referred  to,  in  a  systematic  review,  to  be  as  effec-
tive  as  the  use  of  autogenous  bone  in  severe  maxillary
atrophy.12 NanoBone® (Artoss  GmbH,  Rostock-Warnemünde,
Germany)  was  also  evaluated  as  a  bone  substitute  and
authors  concluded  that  their  use  is  reliable.32 Moreover,
it  seemed  to  be  partially  resorbed  and  replaced  by  new
bone.32
Polymeric  bone  substitutes
The  use  of  biodegradable  polymers  as  a  scaffold  for  cell
culture  has  emerged  as  an  alternative  in  bone  regenera-
tive  therapy.  Several  natural  and  synthetic  polymers  are
being  studied  and  biodegradable  polymers  are  considered
as  the  best  candidates  for  the  construction  of  scaffolds  for
the  tissue  repair.39 Polylactic  acid  (PLA),  polyglycolic  acid
(PGA)  of  polycaprolactone  (PCL)  and  their  copolymers  are
widely  used  in  manufacturing  scaffolds.33 The  choice  of  the
biopolymer  as  a  bone  substitute  is  due  to  biocompatibil-
ity,  reproducibility,  porosity,  cell  adhesion  ability,  besides
being  easily  manipulated.34 Examples  of  biopolymers  used
i
b
l
c105
s  tissue  substitutes  are  polylactic  acid  (PLA),  glycolic
cid  (PGA),  polylactic-coglycolic  acid  (PLGA),  polyethyl-
ne,  polycaprolactone  (PCL)  and  polymethyl  methacrylate
PMMA).  They  can  be  used  as  a  tissue  scaffold  or  as  a  carrier
f  growth  factors.
Authors  evaluated  microscopically  the  behavior  of
isiograft® (Ghimas  SpA  Casalecchiodi  Reno,  Italy)  alone
r  associated  with  Bio-Oss® after  maxillary  sinus  lifting  in
6  patients.35 They  observed  no  inﬂammatory  reaction  in
ll  samples.  Fisiograft® was  present  after  7  months  after
urgery  and  the  newly  formed  bone  with  or  without  beads  of
io-Oss® were  within  conjunctive,  with  primary  structure  of
n  immature  bone  associated  with  a  good  amount  of  lamellar
one.35
A  polymeric,  biodegradable,  biocompatible  and  osteo-
onductor  bone  substitute  formed  by  the  union  of  PLGA
ith  two  phases  of  CaP  and  an  outer  layer  of  CaP  from  3  to
 m  thick,  was  developed  and  its  trade  name  is  OsteoScafTM
BoneTecCorp  --  TRT,  Toronto,  Canada).35,36
OsteoScafTM is  manufactured  by  a  process  of  leaching
nd  phase  inversion,  from  PLGA  and  two  CaP  phases  both
f  which  are  resorbable  by  osteoclasts;  the  ﬁrst  a  par-
iculate  within  the  polymer  structure  and  the  second  a
hin  ubiquitous  coating.  The  outermost  layer,  3--5  m  thick
steoconductive  surface  CaP  abrogates  the  putative  for-
ign  body  giant  cell  response  to  the  underlying  polymer,
hile  the  internal  CaP  phase  provides  dimensional  stabil-
ty  in  an  otherwise  highly  compliant  structure.  Still,  it  has
ufﬁcient  mechanical  strength  to  surgical  manipulation  and
t  can  be  easily  fabricated,  according  to  the  desired  shape
nd  porosity.  The  aspects  of  porosity,  of  around  81--91%
nd  size  between  350  and  1200  m,  favor  the  absorption
apacity  of  blood,  allowing  the  retention  of  clots  and  result-
ng  in  an  osteoconductive  support  for  the  growth  of  the
ost  bone.  Studies  have  revealed  that  it  is  a completely
esorbable  three-phase  matrix,  with  highly  interconnected
acropores.  Three  dimensional  matrices  (scaffolds)  made
rom  this  material,  with  similar  porosity  to  human  cancellous
one,  have  shown  bone  growth  both  in  vitro  and  in  vivo  and
ffer  great  potential  for  application  in  bioengineering.34,36
s  bone  substitute  in  maxillary  sinus  lifting,  OsteoScafTM
emonstrated  both  clinically  and  microscopically  great  per-
ormance  and  clinical  success  after  two  years  of  ﬁnal
ehabilitation  with  implants  in  one  patient.37
iscussion
n  order  to  restore  the  bone  volume  of  this  region,  the  tech-
ique  of  elevation  of  the  maxillary  sinus  membrane  was
eveloped  without  damaging  the  sinusal  membrane  and  over
he  years  this  procedure  has  been  performed  with  a  high
egree  of  predictability  and  low  rate  of  complications.38
urrently,  in  order  to  reconstruct  the  atrophic  maxillae,
ifferent  bone  grafting  techniques  have  emerged  as  autog-
nous,  homogenous  and  heterogenous  grafts,  as  well  as
ynthetic  biomaterials.39 The  ideal  bone  graft  should  possess
eatures  like  an  unlimited  supply,  donor  site  without  morbid-
ty,  lack  of  risk  of  disease  transmission,  high  promotion  in
one  repair,  provide  immediate  stability,  versatility,  excel-
ent  handling  properties,  adequate  life  cycle  and  affordable
ost.40
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In  order  to  overcome  the  limitations  of  autogenous  bone,
everal  studies,  in  humans  and  animals,  searching  the  ideal
one  substitute  have  been  performed,  in  which  the  bio-
aterials  are  evaluated  by  their  clinical,  radiographic,
istological  and  biomechanical  aspects.41 However,  despite
he  vast  number  of  papers  related  to  the  rehabilitation  of
he  posterior  maxilla  associated  with  bone  substitutes,  there
s  no  standardization  of  the  methods  used  for  analysis  hin-
ering  the  election  of  the  best  biomaterial.  Thus,  this  study
imed  to  present  the  clinical  variety  of  bone  substitutes
pplied  in  maxillary  sinus  lifting,  enshrined  in  the  current
cientiﬁc  literature.
Authors  compared  the  response  of  the  Bio-Oss® and
he  autogenous  bone,  in  maxillary  sinus  lifting  of  dogs,
n  periods  of  90  and  180  days,  through  histologic  analy-
is.  At  90  days  showed  that  the  percentage  of  the  contact
rea  bone/implant  was  11.46%  and  52.16%  in  the  autog-
nous  bone  and  Bio-Oss®,  respectively.  At  180  days,  the
io-Oss® continued  with  greater  bone  graft  contact  rate
3.43%,  while  the  autogenous  (42.22%).  The  authors  believe
hat  these  results  happened  because  Bio-Oss® acts  as  a
ermanent  graft.20 In  the  same  experimental  model,  other
uthors  evaluated  histologically  the  simultaneous  installa-
ion  of  endosseous  implants  after  maxillary  sinus  lifting,
ncluding  the  ﬁlling  of  the  cavity  with  lyophilized  human
ortical  bone,  resorbable  hydroxyapatite  or  Bio-Oss®,  at
50  days  period.21 The  results  showed  that  in  the  maxil-
ary  sinuses  ﬁlled  with  lyophilized  bone  grafts  there  was
o  new  bone  formation,  different  from  those  ﬁlled  with
atural  hydroxyapatite  or  with  Bio-Oss®,  which  showed
ew  bone  formation,  with  direct  contact  in  the  surface  of
mplant.21
Authors  compared  different  materials  in  maxillary
inus  lifting  in  humans:  autogenous  bone,  demineralized
yophilized  bone  graft,  Bioglass®,  PepGen  P-15® (associa-
ion  of  anorganic  bovine  material  (Ca2PO4) with  a  synthetic
iomimetic  of  the  15  amino  acid  sequence  of  Type  I  col-
agen,  that  is  responsible  for  cell  binding),  calcium  sulfate
nd  Bio-Oss®.42 The  sample  comprised  of  94  patients  and
62  implants  inserted,  and  each  patient  underwent  biopsy
ithin  a  6  months  period  for  subsequent  histological  analy-
is.  The  authors  concluded  that  all  particles  of  biomaterials
sed  were  surrounded  by  bone  and  all  the  analyzed  biomate-
ials  were  biocompatible  and  improved  the  formation  of  new
one  in  maxillary  sinus  lifting.  The  data  are  very  encourag-
ng  due  to  the  high  number  of  patients  successfully  treated
nd  the  good  quality  of  the  bones  which  were  found  in  the
pecimens  recovered.43
Finally,  the  use  of  autogenous  bone  is  not  always  a  viable
ption,  as  seen  previously,  being  the  reason  for  the  exist-
nce  of  bone  substitutes.  Despite  the  wide  variety  of  bone
ubstitutes  available,  more  clinical  studies  are  necessary,
ith  high  level  of  scientiﬁc  evidence,  analyzing  the  behav-
or  of  the  implant  with  a  long  follow  up,  after  maxillary
inus  lifting,  so  that  we  can  better  conclude  about  the  bone
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